FTC Order Bars Makers of BrainStrong from Making Deceptive Claims
An order from the Federal Trade Commission (FTC) bars the makers of a dietary supplement from making deceptive claims about its effectiveness.
The FTC filed a complaint against i-Health and Martek in June charging that the two companies falsely claimed that they had clinical proof that their product BrainStrong improved adult memory.
Since March 2011, BrainStrong was sold at major retail stores including CVS, Walmart, Walgreens and Rite Aid, and online through drugstore.com and amazon.com for about $30 for a 30-day supply.
The companies advertised the product – which contains the Omega-3 fatty acid DHA – on television, on Twitter, and at brainstrongdha.com.
The final order bars the companies from claiming that any of their products containing DHA prevent cognitive decline or improve memory unless they have clinical evidence.
It also bars the companies from making claims about the health benefits, performance, safety, or effectiveness of such products, unless the claims are supported by competent and reliable scientific evidence.
Finally, the companies cannot claim they have clinical proof when they do not.